Tim Edwards

Executive Chairman

Tim joined Karus as Executive Chairman in 2018. He has extensive management and advisory experience in the biopharmaceutical industry. As well as his role at Karus, Tim is a Director of Ervaxx Limited, a privately-held company developing first-in-class cancer vaccines, incubated by SV Health Investors; and Chair of Storm Therapeutics Limited, working in the field of RNA epigenetics, leveraging insights from the Gurdon Institute, Cambridge. He is also a Non-executive Director of Record PLC, a leading currency management firm; a Trustee of the Institute for Research in Schools; a Governor of Magdalen College School, Oxford; and a Fellow of the RSA, a charity founded in 1754 which drives ideas, innovation and social change.

Previously Tim was a Director and COO of TRex Bio Limited, another of SV Health Investors’ portfolio companies, which is developing the next generation of Regulatory T cell modulators in San Francisco. He was also Chairman of Atopix Therapeutics Limited, acquired by Chiesi Farmaceutici SpA in 2016; President and CEO of Cellzome Inc., acquired by GlaxoSmithKline plc in 2012; a Governing Board member of InnovateUK, the UK’s innovation agency; a Non-Executive Director of the Cell Therapy Catapult; and Chair of the UK BioIndustry Association.